فرنسا - الفرنسية - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

janssen-cilag - ustékinumab - solution injectable

فرنسا - الفرنسية - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

janssen-cilag - ustékinumab - solution injectable

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppresseurs - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

الاتحاد الأوروبي - الفرنسية - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppresseurs - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

كندا - الفرنسية - Health Canada

bausch health, canada inc. - brodalumab - solution - 210mg - brodalumab 210mg - misc. skin and mucous membrane agents

كندا - الفرنسية - Health Canada

abbvie corporation - risankizumab - solution - 90mg - risankizumab 90mg - misc. skin and mucous membrane agents

كندا - الفرنسية - Health Canada

abbvie corporation - risankizumab - solution - 150mg - risankizumab 150mg - misc. skin and mucous membrane agents

كندا - الفرنسية - Health Canada

abbvie corporation - risankizumab - solution - 150mg - risankizumab 150mg - misc. skin and mucous membrane agents

كندا - الفرنسية - Health Canada

abbvie corporation - risankizumab - solution - 360mg - risankizumab 360mg

كندا - الفرنسية - Health Canada

abbvie corporation - risankizumab - solution - 60mg - risankizumab 60mg